In a significant development that could have far-reaching implications for the cannabis industry, health officials in the United States are advocating for the relaxation of restrictions on cannabis.
A prominent figure at the Department of Health and Human Services, Assistant Secretary for Health Rachel Levine, has written a letter to Drug Enforcement Agency administrator Anne Milgram, urging the reclassification of cannabis from a Schedule I to a Schedule III drug under the Controlled Substances Act. The letter, dated August 29 and reported by Bloomberg News, emphasizes that the recommendation is based on a comprehensive review of marijuana’s classification by the Food and Drug Administration.
By reclassifying cannabis to Schedule III, the US health officials are acknowledging its potential for medical use, which could pave the way for expanded research, access, and acceptance.
Sponsored · Selkirk Copper Mines
The Controlled Substances Act categorizes substances based on their medical applications, potential for abuse, and safety considerations. The proposed reclassification is rooted in a belief that cannabis has legitimate medical value while posing a lower risk of abuse compared to substances in the Schedule I category, such as heroin.
The markets have been quick to react to the news, with Trulieve Cannabis (CSE: TRUL), Curaleaf (CSE: CURA) and Green Thumb Industries (CSE: GTII) all experiencing gains of 20% or more in intraday trading.
Information for this story was found via the sources and companies mentioned. The author has no securities or affiliations related to the organizations discussed. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
